Cystic fibrosis microbiome-determined antibiotic therapy trial in exacerbations: results stratified

  • Description
  • Details
  • Subprojects
  • History
  • Relations
  • Publications
Project Title: Cystic fibrosis microbiome-determined antibiotic therapy trial in exacerbations: results stratified
Project Number: CORDIS-109668
Project web address: Follow on CORDIS
Organization: University College Cork, National University Of Ireland, Cork, Ireland, Cork
Collaborators: University Of Washington, US
University Of Dundee, GB
Katholieke Universiteit Leuven, BE
Queen'S University Belfast, IE
Teagasc - Agriculture And Food Development Authority, IE
Arttic, FR
Assistance Publique - Hopitaux De Paris, FR
Universitaetsklinikum Heidelberg, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
Universite Paris Descartes, FR
Hospices Civils De Lyon (Lyon General Hospitals), FR
Clininfo S.A., FR
Papworth Hospital Nhs Foundation Trust, GB
University Hospital Of South Manchester Nhs Foundation Trust, GB
Principal Investigators (PI): Goss Christopher Hooper, US
Birgit Fuchs, DE
Colleen Spence, GB
Thorsten Brietz, DE
David O'Connell, IE
Zoe Kidd, GB
Patrick Chevarier, FR
Mary O'Brien, IE
Karolien Mariën, BE
Martin Dietz, FR
Alix Pillot, FR
Rosaly Datchi, FR
Sophie Jackson, GB
Delphine Maurice, FR
Lesley Howard, GB
 
Project Description:
Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caused by a multitude of organisms that traditionally evolve various mechanisms of resistance. With time, chronic polymicrobial infection develops, with the most dominant infecting organism being Pseudomonas aeruginosa, which is also important in other infections including wounds, burns and patients with medical devices, making it an important clinical target for the EU. In CF infections, empiric intravenous antibiotics are usually given for two weeks. Recurrent infections and treatments result in increasing antimicrobial resistance, and alterations in pathogen host interactions in the lung and gut flora. Next-generation DNA sequencing technology now offers DNA-based personalised diagnostics and treatment strategies. Enhancing our knowledge of the microbiome allows the use of stratified targeted antibacterial therapy that can be compared with standard empirical antibacterial therapy currently used. We believe this will reduce antibiotic usage, optimize dosage and duration startegies as the therapy will be tailored to the actual individual patient needs. Cystic Fibrosis Microbiome-determined Antimicrobial Therapy Trial in Exacerbations: Results Stratified (CF MATTERS) will provide a randomized multi-centre controlled trial of microbiome-derived antimicrobial treatments versus current empirical therapy. Simultaneously parallel human host-pathogen interaction studies in sputa, human gut microflora analysis and evaluation of murine exacerbation models will be performed. This will improve prescription practice and decrease antimicrobial usage and resistance.
 
Project Terms:
life sciences
Project Title: Cystic fibrosis microbiome-determined antibiotic therapy trial in exacerbations: results stratified
Project Number: CORDIS-109668
Project web address: Follow on CORDIS
Organization: University College Cork, National University Of Ireland, Cork, Ireland, Cork
Collaborators: University Of Washington, US
University Of Dundee, GB
Katholieke Universiteit Leuven, BE
Queen'S University Belfast, IE
Teagasc - Agriculture And Food Development Authority, IE
Arttic, FR
Assistance Publique - Hopitaux De Paris, FR
Universitaetsklinikum Heidelberg, DE
Gabo:Mi Gesellschaft Für Ablauforganisation :Milliarium Mbh & Co. Kg, DE
Universite Paris Descartes, FR
Hospices Civils De Lyon (Lyon General Hospitals), FR
Clininfo S.A., FR
Papworth Hospital Nhs Foundation Trust, GB
University Hospital Of South Manchester Nhs Foundation Trust, GB
Principal Investigators (PI): Goss Christopher Hooper, US
Birgit Fuchs, DE
Colleen Spence, GB
Thorsten Brietz, DE
David O'Connell, IE
Zoe Kidd, GB
Patrick Chevarier, FR
Mary O'Brien, IE
Karolien Mariën, BE
Martin Dietz, FR
Alix Pillot, FR
Rosaly Datchi, FR
Sophie Jackson, GB
Delphine Maurice, FR
Lesley Howard, GB
 
Project Categories:
Natural Sciences > Aging Diseases and Pathology, Clinical Trials & Therapy
 
Other Information:
Fiscal Year: 2013
Project Start Date: 1 October 2013
Project End Date: 30 June 2017
Project program: FP7-HEALTH
 
Project Funding Information:
Funding Mechanism: CP-FP - Small or medium-scale focused research project
Year Funding Organization Total Funding, $
2013 European Research Council $8,713,792